Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Truvada with or without HBIg for preventing HBV recurrence post-liver transplant
NCT00507689Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2007
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of emtricitabine + tenofovir disoproxil in hepatitis B (HBV) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With HBV Recurrence at Week 72. Started Sep 2007; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00507689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00507689.